Article
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.
Blood - 27 Nov 2014
Irving Julie, Matheson Elizabeth, Minto Lynne, Blair Helen, Case Marian, Halsey Christina, Swidenbank Isabella, Ponthan Frida, Kirschner-Schwabe Renate, Groeneveld-Krentz Stefanie, Hof Jana, Allan James, Harrison Christine, Vormoor Josef, von Stackelberg Arend, Eckert Cornelia
Abstract excerpt
For most children who relapse with acute lymphoblastic leukemia (ALL), the prognosis is poor, and there is a need for novel therapies to improve outcome. We screened samples from children with B-lineage ALL entered into the ALL-REZ BFM 2002 clinical trial (www.clinicaltrials.gov, #NCT00114348) for somatic mutations activating the Ras pathway (KRAS, NRAS, FLT3, and PTPN11) and showed mutation to be highly...
Topics
- Animals
- Benzimidazoles
- Cell Line, Tumor
- Child
- Clinical Trials as Topic
- Drug Resistance, Neoplasm
- Gene Frequency
- Genes, ras
- Humans
- MAP Kinase Kinase Kinases